5 unknown, 3 completed, 1 recruiting. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Unknown 5, Completed 3, Recruiting 1 |
| Phase 2 | 4 | Unknown 4 |
Follow Deferoxamine: new trials by email Literature Review of Deferoxamine trials Research Report on Deferoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial Deferoxamine, placebo - Intracranial Aneurysm, Subarachnoid Hemorrhage | Phase 1 / Phase 2 | Unknown | Radboud University Medical Center | 40 | 2022-12-02 | 2023-04-24 |
| Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study. Antioxidant therapy, NaCl 0.9% - Acute Myocardial Infarction, Ischemia-reperfusion Injury | Phase 1 | Completed | University of Chile | 18 | 2022-08-09 | 2024-01-12 |
| A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis Deferoxamine (DFO) - Leptomeningeal Metastases | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 32 | 2021-12-22 | 2026-11-18 |
| Application of Desferal to Treat COVID-19 Deferoxamine - COVID-19 | Phase 1 / Phase 2 | Unknown | Kermanshah University of Medical Sciences | 50 | 2020-04-01 | 2020-05-04 |
| The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Conventional TACE, Deferoxamine and conventional TACE - Hepatocellular Carcinoma Non-resectable | Phase 1 | Unknown | Jinan Military General Hospital | 100 | 2018-09-01 | 2019-02-22 |
| Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage deferoxamine, Xingnaojing injection, Normal saline - Intracerebral Hemorrhage | Phase 1 / Phase 2 | Unknown | Capital Medical University | 180 | 2015-03-01 | 2015-05-18 |
| Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major Desferrioxamine, LegalonĀ® (Silymarin), Silymarin (Legalon) - Immune Abnormalities | Phase 1 | Completed | Shiraz University of Medical Sciences | 25 | 2012-06-01 | 2012-12-19 |
| Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both Deferoxamine, Deferasirox - Thalassemia | Phase 1 / Phase 2 | Unknown | Weill Medical College of Cornell University | 6 | 2008-08-01 | 2010-11-05 |
| Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage Deferoxamine Mesylate - Intracerebral Hemorrhage | Phase 1 | Completed | Beth Israel Deaconess Medical Center | 20 | 2008-07-01 | 2018-01-16 |
Cerebral Hemorrhage (2) · COVID-19 (1) · Intracranial Aneurysm (1) · Intracranial Hemorrhages (1) · Meningeal Carcinomatosis (1) · Myocardial Reperfusion Injury (1) · Recurrence (1) · Reperfusion Injury (1) · Stroke (1) · Subarachnoid Hemorrhage (1) · Thalassemia (1) · beta-Thalassemia (1)
Beth Israel Deaconess Medical Center (1) · Capital Medical University (1) · Jinan Military General Hospital (1) · Kermanshah University of Medical Sciences (1) · Memorial Sloan Kettering Cancer Center (1) · Radboud University Medical Center (1) · Shiraz University of Medical Sciences (1) · University of Chile (1) · Weill Medical College of Cornell University (1)
United States (3) · China (2) · Iran (2) · Chile (1) · Netherlands (1)
Abraham IJ Gajardo, MD, PhD (1) · Amir Kiani, PhD (1) · Jeroen Boogaarts, M.D., Ph.D. (1) · Jessica Wilcox, MD (1) · Magdy Selim, MD, PhD (1) · Maolin He, MD (1) · Robert W Grady, Ph.D. (1) · Yadollah Shakiba, MD, PhD (1) · Zahra Amirghofran, PhD (1)
PMID 10051178, PMID 10669330, PMID 11886437, PMID 1406879, PMID 16787239, PMID 18369153, PMID 18552864, PMID 22187937, PMID 22875626, PMID 25076907, PMID 25291189, PMID 28583206, PMID 29619244, PMID 29719970, PMID 33236783, PMID 38973337, PMID 7811060, PMID 8067783, PMID 8554902, PMID 8665150
R01NS057127 (1)